Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

MRD validated as a surrogate endpoint for survival in AML

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

Exploring genomic insights in acute lymphoblastic leukaemia treatment

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types